Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935915 | 0.85 | AVPR1A (0.38) | ADRA2AAVPR1AKCNH2 | |
| SCHEMBL13015184 | 0.85 | KCNH2 (0.39) | AVPR1AKCNH2TNKS2 | |
| SCHEMBL13015187 | 0.80 | CALCRL (0.38) | — | |
| SCHEMBL13015185 | 0.79 | DGAT1 (0.30) | AVPR1A | |
| SCHEMBL15935550 | 0.79 | AVPR1A (0.33) | ADRA2AADRA2BADRA2CADRA1DHTR1D | |
| SCHEMBL13747461 | 0.71 | KCNH2 (0.43) | AVPR1AKCNH2 | |
| SCHEMBL15935918 | 0.69 | KCNH2 (0.39) | AVPR1AKCNH2 | |
| SCHEMBL13015178 | 0.68 | CALCRL (0.51) | — | |
| SCHEMBL15935556 | 0.68 | AVPR1A (0.40) | AVPR1A | |
| SCHEMBL15935551 | 0.68 | CALCRL (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | ADRA2A 39/4885ADRA2B 19/4885ADRA2C 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.